UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 22, 2024

 

Tenax Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-34600

 

26-2593535

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

101 Glen Lennox Drive, Suite 300 

Chapel Hill, North Carolina 27517 

(Address of principal executive offices) (Zip Code)

 

919-855-2100

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

TENX

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01 Other Events.

 

On February 22, 2024, Tenax Therapeutics, Inc. (the “Company”) received written notification from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company had over 500,000 publicly held shares of its common stock and that as a result the Company had regained compliance with Nasdaq Listing Rule 5550(a)(4) (the “Minimum Float Requirement”) and that the matter is now closed.

 

As previously reported, on January 11, 2024, Nasdaq notified the Company that the Company no longer met the Minimum Float Requirement for continued inclusion on the Nasdaq Capital Market.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: February 23, 2024

Tenax Therapeutics, Inc.

 

 

 

 

 

 

By:

/s/ Christopher T. Giordano 

 

 

Christopher T. Giordano

 

 

President and Chief Executive Officer

 

 

 

3

 

 

v3.24.0.1
Cover
Feb. 22, 2024
Cover [Abstract]  
Entity Registrant Name Tenax Therapeutics, Inc.
Entity Central Index Key 0000034956
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Feb. 22, 2024
Entity File Number 001-34600
Entity Incorporation State Country Code DE
Entity Tax Identification Number 26-2593535
Entity Address Address Line 1 101 Glen Lennox Drive
Entity Address Address Line 2 Suite 300
Entity Address City Or Town Chapel Hill
Entity Address State Or Province NC
Entity Address Postal Zip Code 27517
City Area Code 919
Local Phone Number 855-2100
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol TENX
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Tenax Therapeutics (NASDAQ:TENX)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Tenax Therapeutics.
Tenax Therapeutics (NASDAQ:TENX)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Tenax Therapeutics.